The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Raging the War Against Inflammation With Natural Products
Open accessAbstract
Over the last few decade Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are the drugs of choice for treating numerous inflammatory diseases including rheumatoid arthritis. The NSAIDs produces anti-inflammatory activity via inhibiting cyclooxygenase enzyme, responsible for the conversation of arachidonic acid to prostaglandins. Likewise, cyclooxegenase-2 inhibitors (COX-2) selectively inhibit the COX-2 enzyme and produces significantmilar anti-inflammatory, analgesic and anti-pyretic activity without producing COX-1 associated gastrointestinal and renal side effects. Hence during theIn last two decades numerousseveral selective COX-2 inhibitors (COXIBs) have been developed and approved for various inflammatory conditions. However, data from clinical trials have suggested that the prolong use of COX-2 inhibitors are also associated with life threatening cardiovascular side effects including ischemic heart failure and myocardial infection. In these scenario secondary metabolites from natural product offers a great hope for the development of novel anti-inflammatory compounds. Although majority of the natural product based compounds exhibit more selectively towards COX-1. However the data suggest that slight structural modification can be helpful in developing COX-2 selective secondary metabolites with comparative efficacy and limited side effects. Hence thisThis review is an effort to highlight the secondary metabolites from terrestrial and marine source with significant COX-2 and COX-2 mediated PGE2 inhibitory activity,. since it is anticipated thatSince the isolates with ability to inhibit potential to inhibit COX-2 mediated PGE2 production would be useful inare expected to suppressing inflammationthe inflammation and its classical sign and symptoms. Moreover this review has highlighted the potential lead compounds including berberine, kaurenoic acid, α-cyperone, curcumin and zedoarondiol for further development with the help of structure–activity relationship (SAR) studies and their current status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biodiversity hotspots for conservation priorities
Myers, N., Mittermeier, R. A., Mittermeier, C. G., da Fonseca, G. A. B., & Kent, J. (2000) · Nature · doi:10.1038/35002501 · Cited by 31,710
Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
Cancer chemopreventive activity of resveratrol, a natural product derived from grapes
Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W. W., Fong, H. H. S., Farnsworth, N. R., Kinghorn, A. D., Mehta, R. G., et al. (1997) · Science · doi:10.1126/science.275.5297.218 · Cited by 4,935 · cited 1×
“In last two decades several reports have highlighted the anticancer activity of well-established chemo-preventive secondary metabolite resveratrol (31) (Figure 4) (Jang et al., 1997; Bhat and Pezzuto, 2002).”
BackgroundInflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Cyclooxygenases: Structural, cellular, and molecular biology
Smith, W. L., DeWitt, D. L., & Garavito, R. M. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.145 · Cited by 2,925
Points of control in inflammation
Nathan, C. (2002) · Nature · doi:10.1038/nature01320 · Cited by 2,738
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · cited 1×
“Hence it is proposed that early treat with NSAIDs or selective COX-2 can ameliorate or even slow down the clinical manifestation of AD (Weggen et al., 2001; Sciulli et al., 2005).”
BackgroundThe role of inflammation in CNS injury and disease
Lucas, S., Rothwell, N. J., & Gibson, R. M. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706400 · Cited by 1,272
Murakami, M., Naraba, H., Tanioka, T., Semmyo, N., Nakatani, Y., Kojima, F., Ikeda, T., Fueki, M., Ueno, A., Oh-ishi, S., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003505200 · Cited by 964
Prostaglandin E2 synthesis and secretion: The role of PGE2 synthases
Park, J. Y., Pillinger, M. H., & Abramson, S. B. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.01.016 · Cited by 793
Altered pain perception and inflammatory response in mice lacking prostacyclin receptor
Murata, T., Ushikubi, F., Matsuoka, T., Hirata, M., Yamasaki, A., Sugimoto, Y., Ichikawa, A., Aze, Y., Tanaka, T., Yoshida, N., et al. (1997) · Nature · doi:10.1038/41780 · Cited by 773
Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3
Ushikubi, F., Segi, E., Sugimoto, Y., Murata, T., Matsuoka, T., Kobayashi, T., Hizaki, H., Tuboi, K., Katsuyama, M., Ichikawa, A., et al. (1998) · Nature · doi:10.1038/26233 · Cited by 677 · cited 1×
“These studies have also been helpful in exploring the specific EP subtypes agonist/antagonist that can be used to innervate, identify and pinpoint the EP sub-types involved in carrying out multifaceted PGE2 pathophysiological actions (Ushikubi et al., 1998).”
BackgroundSurh, Y.-J. (1999) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s1383-5742(99)00057-5 · Cited by 633
A calculated response: control of inflammation by the innate immune system
Barton, G. M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34431 · Cited by 532
Aggarwal, S., Ichikawa, H., Takada, Y., Sandur, S. K., Shishodia, S., & Aggarwal, B. B. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.017400 · Cited by 532
Prostaglandin E2-induced inflammation: Relevance of prostaglandin E receptors
Kawahara, K., Hohjoh, H., Inazumi, T., Tsuchiya, S., & Sugimoto, Y. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.07.008 · Cited by 488
Langenbach, R., Loftin, C., Lee, C., & Tiano, H. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00158-6 · Cited by 230 · cited 4×
“Which is based upon an observation that intrathecal LPS administration in COX-1 knock-out mice have ameliorated the inflammatory response, while in COX-2 knock out mice inflammation was exacerbated (Langenbach et al., 1999; Smith and Langenbach, 2001; Ueno et al., 2005; Aid et al., 2008).”
BackgroundResultInfluentialCandelario-Jalil, E., de Oliveira, A. C. P., Gräf, S., Bhatia, H. S., Hüll, M., Muñoz, E., & Fiebich, B. L. (2007) · Journal of Neuroinflammation · doi:10.1186/1742-2094-4-25 · Cited by 223
Cited by
Ginwala, R., Bhavsar, R., Chigbu, D. G. I., Jain, P., & Khan, Z. K. (2019) · Antioxidants · doi:10.3390/antiox8020035 · Cited by 588
Nkadimeng, S. M., Steinmann, C. M., & Eloff, J. N. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s317182 · Cited by 83
Insights on the anticandidal activity of non-antifungal drugs
Moraes, D. C., & Ferreira-Pereira, A. (2019) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2019.07.004 · Cited by 37
Metadata
- Authors
- Attiq, A., Jalil, J., Husain, K., & Ahmad, W.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2018-09-07
- Volume
- 9
- Pages
- 976-976
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2889707681
- Cited by
- 211
- References
- 18
- FWCI
- 8.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.